These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31082669)

  • 1. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
    Morris MJ; Loriot Y; Sweeney CJ; Fizazi K; Ryan CJ; Shevrin DH; Antonarakis ES; Pandit-Taskar N; Deandreis D; Jacene HA; Vesselle H; Petrenciuc O; Lu C; Carrasquillo JA; Higano CS
    Eur J Cancer; 2019 Jun; 114():107-116. PubMed ID: 31082669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
    Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
    Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
    Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
    Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
    Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
    Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
    Sartor O; Hoskin P; Coleman RE; Nilsson S; Vogelzang NJ; Petrenciuc O; Staudacher K; Thuresson M; Parker C
    Prostate; 2016 Jul; 76(10):905-16. PubMed ID: 27004570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
    Chi KN; Higano CS; Blumenstein B; Ferrero JM; Reeves J; Feyerabend S; Gravis G; Merseburger AS; Stenzl A; Bergman AM; Mukherjee SD; Zalewski P; Saad F; Jacobs C; Gleave M; de Bono JS
    Lancet Oncol; 2017 Apr; 18(4):473-485. PubMed ID: 28283282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.
    Fizazi K; González Mella P; Castellano D; Minatta JN; Rezazadeh Kalebasty A; Shaffer D; Vázquez Limón JC; Sánchez López HM; Armstrong AJ; Horvath L; Bastos DA; Amin NP; Li J; Unsal-Kacmaz K; Retz M; Saad F; Petrylak DP; Pachynski RK
    Eur J Cancer; 2022 Jan; 160():61-71. PubMed ID: 34802864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
    Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T
    Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
    Nilsson S
    Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
    Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
    Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
    ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
    George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
    Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.
    Caffo O; Ortega C; Nolè F; Gasparro D; Mucciarini C; Aieta M; Zagonel V; Iacovelli R; De Giorgi U; Facchini G; Veccia A; Palesandro E; Verri E; Buti S; Razzini G; Bozza G; Maruzzo M; Ciccarese C; Schepisi G; Rossetti S; Maines F; Kinspergher S; Fratino L; Ermacora P; Nicodemo M; Giordano M; Sartori D; Scapoli D; Sabbatini R; Lo Re G; Morelli F; D'Angelo A; Vittimberga I; Lippe P; Carrozza F; Messina C; Galli L; Valcamonico F; Porta C; Pappagallo G; Aglietta M
    Eur J Cancer; 2021 Sep; 155():56-63. PubMed ID: 34358777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
    Cursano MC; Iuliani M; Casadei C; Stellato M; Tonini G; Paganelli G; Santini D; De Giorgi U
    Crit Rev Oncol Hematol; 2020 Feb; 146():102864. PubMed ID: 31986318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
    Araujo JC; Trudel GC; Saad F; Armstrong AJ; Yu EY; Bellmunt J; Wilding G; McCaffrey J; Serrano SV; Matveev VB; Efstathiou E; Oudard S; Morris MJ; Sizer B; Goebell PJ; Heidenreich A; de Bono JS; Begbie S; Hong JH; Richardet E; Gallardo E; Paliwal P; Durham S; Cheng S; Logothetis CJ
    Lancet Oncol; 2013 Dec; 14(13):1307-16. PubMed ID: 24211163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
    Higano CS; Dizdarevic S; Logue J; Richardson T; George S; de Jong I; Tomaszewski JJ; Saad F; Miller K; Meltzer J; Sandström P; Verholen F; Tombal B; Sartor O
    Cancer; 2024 Jun; 130(11):1930-1939. PubMed ID: 38340349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.